|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Faslodex
|
|
gptkbp:activities
|
estrogen receptor antagonist
|
|
gptkbp:appointed_by
|
injection
|
|
gptkbp:approves
|
gptkb:2002
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Faslodex
|
|
gptkbp:clinical_trial
|
gptkb:hormone_receptor-positive_breast_cancer
Phase III
|
|
gptkbp:contraindication
|
pregnancy
lactation
|
|
gptkbp:counseling_services
|
inform healthcare provider of all medications
avoid pregnancy during treatment
discuss potential side effects with healthcare provider
keep all follow-up appointments
report any signs of liver dysfunction
|
|
gptkbp:developed_by
|
gptkb:temple
|
|
gptkbp:dosage_form
|
solution for injection
|
|
gptkbp:excretion
|
urine
bile
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
fulvestrant
|
|
gptkbp:indication
|
ER-positive breast cancer
|
|
gptkbp:ingredients
|
gptkb:fulvestrant
C18 H18 F3 N3 O3 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
gptkb:2020
|
|
gptkbp:is_atype_of
|
L02 B A03
|
|
gptkbp:is_monitored_by
|
liver function tests
blood cell counts
|
|
gptkbp:is_used_for
|
breast cancer treatment
|
|
gptkbp:lifespan
|
approximately 40 days
|
|
gptkbp:manager
|
intramuscular
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pharmacokinetics
|
highly protein-bound
downregulates estrogen receptors
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
injection site reactions
hot flashes
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:target_audience
|
postmenopausal women
|
|
gptkbp:treatment
|
gptkb:palbociclib
gptkb:everolimus
gptkb:ribociclib
second-line therapy
|